HanAll Biopharma Reports Operating Profit of 10 Billion KRW, Up 70% Year-on-Year

[Asia Economy Reporter Minji Lee] HanAll Biopharma announced on the 18th that its operating profit reached 10 billion KRW, a 70% increase compared to the same period last year. Sales increased by 14% to 101.5 billion KRW, while net profit decreased by 49% to 9.9 billion KRW.

The company stated, "Operating profit increased due to stable sales growth of key products and milestone inflows from clinical development," adding, "The net profit for the previous fiscal year reflected a temporary impact from the issuance of share Earnout by our global partner, Immunovant."